头雁|11月 21, 2026 08:29
Steve Jobs died of pancreatic cancer, a disease previously notoriously difficult to cure. It seems there's new progress. The company developing this drug to control pancreatic cancer growth is Revolution Medicines (NASDAQ: RVMD), with a market capitalization of approximately $34 billion.
This is the first targeted therapy approved for pancreatic cancer. It has also been approved in Europe.
The company's published treatment data:
Revolution Medicines presented first-line combination therapy data from its Phase 1/2 trial at the symposium (ENA 2026):
In 61 patients with metastatic pancreatic cancer treated as first-line therapy:
- Disease control rate (DCR): 90.2% – Tumor shrinkage or cessation of growth.
- Objective response rate (ORR): 60.7% – Actual tumor shrinkage, with 8.2% achieving complete response (tumor disappearance on imaging).
- Median progression-free survival (PFS): 12.8 months.
- 12-month overall survival: Approximately 76.6%.
Share To
HotFlash
APP
X
Telegram
CopyLink